Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 18/20 | 1.00 |
| ▸ | STK4 | Q13043 | 10/20 | 1.00 |
| ▸ | STK3 | Q13188 | 10/20 | 1.00 |
| ▸ | MST1 | P26927 | 1/20 | 0.67 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14162963 | 0.83 | CHEK1 (0.76) | LRRK2STK4STK3STK26 | |
| SCHEMBL15401357 | 0.83 | LRRK2 (1.00) | LRRK2STK4STK3MST1STK26 | |
| SCHEMBL15401589 | 0.83 | LRRK2 (1.00) | LRRK2STK4STK3MST1STK26 | |
| SCHEMBL15401738 | 0.83 | LRRK2 (1.00) | LRRK2STK4STK3MST1STK26 | |
| SCHEMBL15401123 | 0.83 | LRRK2 (1.00) | LRRK2STK4STK3MST1STK26 | |
| SCHEMBL15400907 | 0.82 | LRRK2 (1.00) | LRRK2STK4STK3 | |
| SCHEMBL31301767 | 0.81 | STK4 (0.73) | LRRK2STK4STK3 | |
| SCHEMBL18967909 | 0.81 | LRRK2 (1.00) | LRRK2STK4STK3 | |
| SCHEMBL15401511 | 0.81 | LRRK2 (1.00) | LRRK2STK4STK3 | |
| SCHEMBL15400511 | 0.81 | LRRK2 (1.00) | LRRK2STK4STK3MST1STK26 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-02-13 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | STK3, STK4, STK36 | LRRK2 210/4885STK4 2/4885STK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.